Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00116571

Enrollment

180

Registered

2005-06-30

Start date

2005-05-31

Completion date

2006-12-31

Last updated

2006-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Keywords

Benign Prostatic Hyperplasia (BPH), Photodynamic Therapy (PDT), Lower Urinary Tract Symptoms (LUTS)

Brief summary

The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as PDT) is a treatment that uses light to make a drug work. This means the drug is light-activated. Light-activated drugs do not work until a certain color of light shines on the drug. When the drug and the light combine, they react together to destroy tissue. This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary symptoms go back to normal.

Detailed description

This is a multi-center, randomized, sham-controlled, double-blind, dose-finding study in parallel groups of subjects with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). All subjects will receive a fixed dose of lemuteporfin injected transurethrally into the prostate followed by transurethral application of either one of three active light doses or a sham light dose. Subjects will be followed for safety and efficacy for a minimum of three months to a maximum of 12 months. The primary study endpoint will be the change from baseline in AUA SI score at three months.

Interventions

DRUGLemuteporfin for injection

DEVICETransurethral drug delivery system

DEVICETransurethral light delivery system

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men 21 years of age and older. * Subjects with LUTS due to BPH with AUA SI scores of 13 and over and Qmax between 5 and 15 mL/sec. * Subjects with urethral treatment length of at least 25 mm.

Exclusion criteria

* Subjects who have had previous minimally invasive or surgical treatment for BPH. * Subjects who have unsuitable prostate dimensions.

Design outcomes

Primary

Measure	Time frame
The change from baseline in American Urological Association Symptom Index (AUA SI) score at the Month 3 visit	—

Secondary

Measure	Time frame
Responder rate	—
Change from baseline in Qmax	—
Change from baseline in post-void residual (PVR)	—
Shifts from baseline in subject responses to the BPH Quality of Life Impact Assessment	—
Safety outcomes: adverse events, clinical laboratory tests, vital signs, dysuria, and Male Sexual Health Questionnaire (MSHQ)	—

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026